Historical Valuation
ADMA Biologics Inc (ADMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.07 is considered Undervalued compared with the five-year average of 0.85. The fair price of ADMA Biologics Inc (ADMA) is between 57.11 to 67.78 according to relative valuation methord. Compared to the current price of 17.95 USD , ADMA Biologics Inc is Undervalued By 68.57%.
Relative Value
Fair Zone
57.11-67.78
Current Price：17.95
68.57%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ADMA Biologics Inc (ADMA) has a current Price-to-Book (P/B) ratio of 9.88. Compared to its 3-year average P/B ratio of 10.78 , the current P/B ratio is approximately -8.30% higher. Relative to its 5-year average P/B ratio of 7.61, the current P/B ratio is about 29.82% higher. ADMA Biologics Inc (ADMA) has a Forward Free Cash Flow (FCF) yield of approximately 0.96%. Compared to its 3-year average FCF yield of -1.19%, the current FCF yield is approximately -180.28% lower. Relative to its 5-year average FCF yield of -18.15% , the current FCF yield is about -105.27% lower.
P/B
Median3y
10.78
Median5y
7.61
FCF Yield
Median3y
-1.19
Median5y
-18.15
Competitors Valuation Multiple
AI Analysis for ADMA
The average P/S ratio for ADMA competitors is 91.21, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA.O) exhibits a P/S ratio of 7.07, which is -92.25% above the industry average. Given its robust revenue growth of 12.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ADMA
1Y
3Y
5Y
Market capitalization of ADMA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ADMA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ADMA currently overvalued or undervalued?
ADMA Biologics Inc (ADMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.07 is considered Undervalued compared with the five-year average of 0.85. The fair price of ADMA Biologics Inc (ADMA) is between 57.11 to 67.78 according to relative valuation methord. Compared to the current price of 17.95 USD , ADMA Biologics Inc is Undervalued By 68.57% .
What is ADMA Biologics Inc (ADMA) fair value?
ADMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ADMA Biologics Inc (ADMA) is between 57.11 to 67.78 according to relative valuation methord.
How does ADMA's valuation metrics compare to the industry average?
The average P/S ratio for ADMA's competitors is 91.21, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA) exhibits a P/S ratio of 7.07, which is -92.25% above the industry average. Given its robust revenue growth of 12.00%, this premium appears unsustainable.
What is the current P/B ratio for ADMA Biologics Inc (ADMA) as of Jan 10 2026?
As of Jan 10 2026, ADMA Biologics Inc (ADMA) has a P/B ratio of 9.88. This indicates that the market values ADMA at 9.88 times its book value.
What is the current FCF Yield for ADMA Biologics Inc (ADMA) as of Jan 10 2026?
As of Jan 10 2026, ADMA Biologics Inc (ADMA) has a FCF Yield of 0.96%. This means that for every dollar of ADMA Biologics Inc’s market capitalization, the company generates 0.96 cents in free cash flow.
What is the current Forward P/E ratio for ADMA Biologics Inc (ADMA) as of Jan 10 2026?
As of Jan 10 2026, ADMA Biologics Inc (ADMA) has a Forward P/E ratio of 21.80. This means the market is willing to pay $21.80 for every dollar of ADMA Biologics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ADMA Biologics Inc (ADMA) as of Jan 10 2026?
As of Jan 10 2026, ADMA Biologics Inc (ADMA) has a Forward P/S ratio of 7.07. This means the market is valuing ADMA at $7.07 for every dollar of expected revenue over the next 12 months.